Comparative Pharmacology
Head-to-head clinical analysis: DUONEB versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUONEB versus HICON.
DUONEB vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUONEB is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors in bronchial smooth muscle, reducing vagal tone and bronchodilation. Albuterol stimulates beta-2 adrenergic receptors, leading to relaxation of bronchial smooth muscle.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
1-2 vials (2.5 mg ipratropium bromide/2.5 mg albuterol sulfate per 3 mL vial) via nebulization every 6 hours as needed; maximum 6 vials per day.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Ipratropium: terminal half-life ~2 hours (range 1.5-4 hours). Albuterol: terminal half-life 3.8-6 hours (mean ~4.6 hours). Clinical context: Both contribute to bronchodilation lasting 4-6 hours.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
DuoNeb (ipratropium bromide/albuterol sulfate) is a fixed-dose combination. Ipratropium: 90% excreted unchanged in feces (biliary), <10% renal. Albuterol: 60-70% renal as unchanged drug and metabolites (sulfate conjugate), 30-40% fecal.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic/Beta2-Agonist Combination
Anticholinergic